# Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer

> **NCT05169853** · — · ACTIVE_NOT_RECRUITING · sponsor: **Ain Shams University** · enrollment: 80 (estimated)

## Conditions studied

- Triple Negative Breast Cancer
- HER2-positive Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05169853
- **Lead sponsor:** Ain Shams University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-01
- **Primary completion:** 2024-10-30
- **Final completion:** 2024-10-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05169853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05169853, "Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05169853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*